BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Doxorubicin
,
rs7903146
,
NEUROG3
,
Apoptosis
,
Obesity
,
Adipose tissue
,
Pharmacogenetics
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
MYC
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
B lymphocyte (IgM memory) of spleen
Vena cava
Granulocyte-macrophage progenitor cell of bone marrow
B lymphocyte (naive) of spleen
Omental adipose tissue
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Hyperoxia
B-cell lymphoma
Whipple's disease
Physical activity
Irritable bowel syndrome
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
CEP 14083
microcystin RR
FGF10 protein, human
Quinacrine
CGP 60474
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Bcl6
MIR141
PRKDC
PRKAR1B
MAP2K7
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Survey of activation-induced genome architecture reveals a novel enhancer of Myc.
Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target i…
MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding site…
Therapeutic targeting of "undruggable" MYC.
Development and Characterization of Benzoselenazole Derivatives as Potent and Selective c-MYC Transc…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Dose-adjusted EPOCH-R in MYC Positive DLBCL
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myelo…
Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients …
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ